Funding Data Link References Status API Help
type
year
publication
category
publisher
funder name
source
Page 1 of 48961 results
Sort by: relevance publication year

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins

Journal Article published 9 Jul 2018 in Clinical Cancer Research volume 24 issue 23 on pages 5807 to 5814

Authors: Ed S. Kheder, David S. Hong

9124 Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)

Journal Article published Sep 2009 in European Journal of Cancer Supplements volume 7 issue 2 on page 542

Authors: D.C. Christoph, T.C. Gauler, F. Gamarra, H.G. Fuhr, J.R. Fischer, C. Gonschorek, N. Frickhofen, R.M. Huber, M. Schuler, W.E.E. Eberhardt

P76 Clinical experiences with therapeutic derivatives of the anti-ED-B fibronectin immunoprotein L19

Journal Article published Nov 2007 in European Journal of Cancer Supplements volume 5 issue 8 on page 33

Authors: G. Spitaleri, G. Curigliano, T. DePas, C. Noberasco, G. Paganelli, L. Giovannoni, L. Zardi, D. Neri, H. Menssen, F. De Braud

6606 POSTER Three drug regimen in SCLC-ED patients: a phase II study

Journal Article published Sep 2007 in European Journal of Cancer Supplements volume 5 issue 4 on page 390

Authors: K. Syrigos, K. Pantazopoulos, A. Charpidou, I. Gkiozos, I. Tzannou, C. Alamara, K. Dilana, E. Kotteas, N. Katirtzoglou

Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16–20 March 2004

Journal Article published 18 May 2004 in Breast Cancer Research volume 6 issue 4

Authors: Elżbieta Senkus-Konefka, Jacek Jassem

Clinical implications of germline mutations in breast cancer genes: RECQL

Journal Article published 4 Jan 2019 in Breast Cancer Research and Treatment

Research funded by European Research Council (310018)

Authors: A. Ramsay Bowden, Marc Tischkowitz

9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial

Journal Article published Sep 2009 in European Journal of Cancer Supplements volume 7 issue 2 on page 541

Authors: D.S. Ettinger, R. Jotte, P. Lorigan, V. Gupta, L. Garbo, D. Spigel, A.Z. Dudek, R. Salgia, R. McNally, M. Renschler

9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

Journal Article published Sep 2009 in European Journal of Cancer Supplements volume 7 issue 2 on pages 540 to 541

Authors: R. Jotte, P.R. Conkling, C. Reynolds, C. Shah, M. Galsky, L. Klein, J.F. Fitzgibbons, R. McNally, J.W. Oliver, M. Renschler

Omission of surgery in elderly patients with early stage breast cancer

Journal Article published Feb 2013 in European Journal of Cancer volume 49 issue 3 on pages 545 to 552

Research funded by KWF Kankerbestrijding (KWF 2007-3968)

Authors: Marije E. Hamaker, Esther Bastiaannet, Dorothea Evers, Willemien van de Water, Carolien H. Smorenburg, Ed Maartense, Anneke M. Zeilemaker, Gerrit-Jan Liefers, Lydia van der Geest, Sophia E. de Rooij, Barbara C. van Munster, Johanneke E.A. Portielje

4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

Journal Article published Sep 2009 in European Journal of Cancer Supplements volume 7 issue 3 on page 3

Authors: G.G. Steger, R. Greil, R. Jakesz, A. Lang, B. Mlineritsch, E. Melbinger-Zeinitzer, C. Marth, H. Samonigg, E. Kubista, M. Gnant